Pediatric Oncology I Panel

Series Editors:
Marcia L. Buck, Pharm.D., BCPPS, FCCP, FPPAG
Clinical Coordinator
University of Virginia Children's Hospital
Professor
Department of Pediatrics
University of Virginia School of Medicine
Clinical Professor
Virginia Commonwealth University School of Pharmacy
Department of Pharmacy Services
University of Virginia Health System
Charlottesville, Virginia
Kalen B. Manasco, Pharm.D., FCCP, BCPS
Clinical Professor
University of Florida College of Pharmacy
Gainesville, Florida

Faculty Panel Chair:
Betsy M. Bickert Poon, Pharm.D., FCCP
Assistant Director of Pharmacy
Disney Pavilion at Florida Hospital for Children
Brandon, Florida

PEDIATRIC CANCER TREATMENT DEVELOPMENT

Authors
Cynthia Jiles, R.Ph., BSPharm
Senior Clinical Research Pharmacist
Pharmaceutical Management Branch
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
Rockville, Maryland
Eileen Wu, Pharm.D.
Senior Clinical Research Pharmacist
Pharmaceutical Management Branch
Cancer Therapy Evaluation Program
Division of Cancer Treatment and Development
National Cancer Institute
Rockville, Maryland

Reviewers
M. Brooke Bernhardt, Pharm.D., M.S., BCOP, BCPPS
Assistant Director of Clinical Services and Outcomes
Pharmacy Department
Texas Children's Hospital
Houston, Texas

Salem Kamalay, Pharm.D., BCPS, BCPPS
Clinical Pharmacist
Department of Pharmaceutical Services
University of California, San Francisco Medical Center
San Francisco, California

ASPARAGINASE MONITORING IN PATIENTS WITH LEUKEMIA

Author
Tamara MacDonald, Pharm.D.
Clinical Pharmacy Specialist
Hematology/Oncology
Faculties of Medicine and Health Professions,
Dalhousie University/IWK Health Centre
Halifax, Nova Scotia

Reviewers
Kerry Parsons, Pharm.D., FHOPA, BCOP
Oncology Medical Science Liaison
AstraZeneca Pharmaceuticals
Helena, Alabama
Manal M. Abouelkheir, Pharm.D., BCPS, BCPPS
Pediatric Clinical Pharmacist
Department of Pharmacy Services
King Saud University Medical City
Adjunct Assistant Professor
Department of Clinical Pharmacy
College of Pharmacy-King Saud University
Riyadh, Saudi Arabia
Melissa Ray, Pharm.D., BCPS, BCPPS
Clinical Pharmacist III
United Health Group
Tampa, Florida
Clinical Assistant Professor of Pharmacy Practice
University of Florida College of Pharmacy
Gainesville, Florida

BIOSIMILAR USE IN PEDIATRIC ONCOLOGY

Author
Rachel Langley, Pharm.D., BCPPS
Hematology/Oncology Clinical Pharmacist
St. Louis Children's Hospital
St. Louis, Missouri
Reviewers

Olga Militano, Pharm.D.
Pharmacist
Study Development Office
Children's Oncology Group
Monrovia, California

Allison L. Salinas, Pharm.D., BCPPS
Clinical Pharmacist
Children's Hospital Colorado
Aurora, Colorado

Tara Leigh Smith, Pharm.D., M.S., BCPPS
Clinical Pharmacy Manager
Sacred Heart hospital
Gulf Breeze, Florida

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Pediatric Oncology I:

Emilie L. Karpiuk, Pharm.D., BCPS
Oncology Pharmacist
Department of Pharmacy
Froedtert Hospital
Milwaukee, Wisconsin

Lynn Kassel, Pharm.D., BCPS
Assistant Professor
Department of Clinical Sciences
Drake University College of Pharmacy & Health Sciences
Des Moines, Iowa
Acute Care Pharmacist
Mercy West Lakes Hospital
Clive, Iowa
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Consultancies: Nicole Arwood (Navigant Consulting, Inc.); Rachel Langley (Syntaxx Communications); Melissa Ray (Therapeutics Research Center);

Stock Ownership: Jeanne M. Brady (Charles Schwab)

Royalties:

Grants: Tamara MacDonald (Jazz Pharmaceuticals); Yee Chang Soh (Ministry of Education, Malaysia, Universiti Teknologi); Devona Williams (Jazz Pharmaceuticals)

Honoraria: Tamara MacDonald (Syntaxx Communications); Yee Chang Soh (UCSI University Kuala Lumpur, Malaysia); Devona Williams (Jazz Pharmaceuticals)

Other: Kerry Parsons (employed by AstraZeneca Pharmaceuticals)

Nothing to disclose: M. Brooke Bernhardt; Elizabeth A. Boucher; Shane Cross; Rebecca Deoras; Manal M. Abou Elkheir; Karen Gradischer; Amy Helvie; Cynthia Jiles; Salem Kamalay; Olga Militano; Margaret Oates Poisson; Andrew Ostrenga; Jennifer L. Pau- ley; Allison L. Salinas; Caroline M. Sierra; Tara Leigh Smith; Brenda Winger; Eileen Wu

ROLE OF BPS: The Board of Pharmacy Specialties (BPS) is an autonomous division of the American Pharmacists Association (APhA). BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PedSAP has been approved by BPS for use in BCPPS recertification. Information about the BPS recertification process is available online.

Questions regarding BCPPS recertification should be directed to:

Board of Pharmacy Specialties
2215 Constitution Avenue NW
Washington, DC 20037
(202) 429-7591